Stock-based Compensation (Tables)
|
6 Months Ended |
Jun. 30, 2026 |
|---|
| Share-Based Payment Arrangement [Abstract] |
|
| Schedule of Stock Option Activity |
Stock option activity for the six months ended June 30, 2026 was as follows: | | | | | | | | | | | | | | | | | | | | | | | | | Number of
Shares
Underlying
Outstanding
Options | | Weighted-
Average Exercise
Price | | Weighted-
Average
Remaining
Contractual
Term (in years) | | Aggregate
Intrinsic
Value | | Outstanding—December 31, 2025 | 1,710,622 | | | $ | 7.69 | | | 4.72 | | $ | 24,142 | | | Options exercised | (443,815) | | | 5.28 | | | | | | | | | | | | | | | Outstanding—June 30, 2026 | 1,266,807 | | | $ | 8.54 | | | 4.22 | | $ | 68,385 | | | Vested —June 30, 2026 | 1,266,807 | | | $ | 8.54 | | | 4.22 | | $ | 68,385 | | | Exercisable—June 30, 2026 | 1,266,807 | | | $ | 8.54 | | | 4.22 | | $ | 68,385 | |
|
| Schedule of Stock Options Outstanding and Exercisable |
The following table summarizes information about stock options outstanding and exercisable at June 30, 2026. | | | | | | | | | | | | | | | | | | | | | | | Options Outstanding | | Options
Exercisable | Exercise
Price | | Options
Outstanding | | Weighted
Average
Remaining
Contractual
Life (Years) | | | $ | 1.85 | | | 159,294 | | | 4.04 | | 159,294 | | | $ | 2.13 | | | 461,616 | | | 4.25 | | 461,616 | | | $ | 14.22 | | | 636,688 | | | 4.25 | | 636,688 | | | $ | 52.40 | | | 9,209 | | | 3.25 | | 9,209 | | | | 1,266,807 | | | | | 1,266,807 | |
|
| Schedule of Nonvested Restricted Stock Units Activity |
A summary of RSU activity for the six months ended June 30, 2026 was as follows: | | | | | | | | | | | | | Number of
Shares | | Weighted Average
Grant Date Fair
Value (per share) | | Unvested—December 31, 2025 | 4,085,075 | | | $ | 12.02 | | | Granted | 2,346,589 | | | 25.41 | | | Canceled | (136,224) | | | 14.21 | | | Vested | (1,503,118) | | | 12.13 | | | Unvested—June 30, 2026 | 4,792,322 | | | $ | 18.48 | |
|
| Schedule of Stock-based Compensation |
The Company recognized stock-based compensation expense for all share-based awards in the unaudited condensed consolidated statements of operations and comprehensive loss as follows (in thousands): | | | | | | | | | | | | | | | | | | | | | | | | | | | | | Three Months Ended June 30, | | Six Months Ended June 30, | | | 2026 | | 2025 | | 2026 | | 2025 | | | | | | Cost of revenue | $ | 1,395 | | | $ | 1,799 | | | $ | 2,221 | | | $ | 2,935 | | | | | | | Research and development | 4,332 | | | 6,303 | | | 6,948 | | | 10,608 | | | | | | | Sales and marketing | 1,177 | | | 1,733 | | | 1,943 | | | 2,839 | | | | | | | General and administrative | 4,481 | | | 3,391 | | | 7,767 | | | 5,342 | | | | | | | Total stock-based compensation | $ | 11,385 | | | $ | 13,226 | | | $ | 18,879 | | | $ | 21,724 | | | | | |
The following table summarizes stock-based compensation expense by award type (in thousands): | | | | | | | | | | | | | | | | | | | | | | | | | | | | | Three Months Ended June 30, | | Six Months Ended June 30, | | | 2026 | | 2025 | | 2026 | | 2025 | | | | | | RSUs | $ | 10,219 | | | $ | 11,971 | | | $ | 16,668 | | | $ | 19,304 | | | | | | | | | | | | | | | | | | | Employee stock purchase plan | 377 | | | 291 | | | 738 | | | 631 | | | | | | | RSAs | — | | | 964 | | | — | | | 1,789 | | | | | | | Stereolabs post‑combination compensation expense | 789 | | | — | | | 1,473 | | | — | | | | | | | Total stock-based compensation | $ | 11,385 | | | $ | 13,226 | | | $ | 18,879 | | | $ | 21,724 | | | | | |
|